Human immunodeficiency virus‐associated prostate cancer: clinicopathological findings and outcome in a multi‐institutional study
Open Access
- 2 April 2008
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 101 (12), 1519-1523
- https://doi.org/10.1111/j.1464-410x.2008.07474.x
Abstract
To characterize the clinicopathological findings and the outcome of human immunodeficiency virus (HIV)-infected patients diagnosed and treated for prostate carcinoma, as HIV-positive men being treated with highly active antiretroviral therapy (HAART) are living longer and thus are more likely to develop cancers such as prostate cancer. We performed a retrospective, multi-institutional study involving HIV-positive men with concomitant prostate carcinoma. We collected data regarding patient demographics (age, race), HIV status (CD4(+) cell count, HIV viral load, HAART), PSA level (at cancer diagnosis), symptoms and signs, radiological findings, pathology (Gleason score, stage), cancer treatment (type, side-effects), and outcome (response, survival). Accrued data was analysed using descriptive statistics. We identified 17 patients (mean age 59 years) with HIV-associated prostate adenocarcinoma. The mean CD4(+) count was 336 cells/mm(3) and the mean HIV viral load was 17 319 copies/mL. In all, 14 (82%) of these men were receiving HAART. Most patients were diagnosed with carcinoma after an abnormal screening PSA level. The mean PSA level was 30 ng/mL. Only six (35%) men had an abnormal prostate on examination. The mean Gleason score was 6.8, and in most cases, cancer was confined to the prostate gland. Most patients were amenable to curative treatment with hormonal therapy, radiation, and/or prostatectomy. There were no serious treatment related side-effects. One patient remained untreated. All treated patients had a complete response (undetectable PSA level). Most patients were long-term survivors. Documented death in five cases was unrelated to prostate cancer. The management of HIV-positive men with prostate carcinoma in the HAART era is becoming increasingly important. Our data shows that in men receiving HAART, their age, PSA levels, clinical presentation, management, and outcome from treated prostate carcinoma does not appear to be significantly altered by HIV status. Therefore, we recommend that patients with prostate cancer and well-controlled HIV viraemia be managed similarly to their HIV-negative counterparts.Keywords
This publication has 35 references indexed in Scilit:
- Human Herpesvirus 8 Seroprevalence among Prostate Cancer Case Patients and Control SubjectsThe Journal of Infectious Diseases, 2007
- Inflammation in prostate carcinogenesisNature Reviews Cancer, 2007
- Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features: Open questions for urologists, oncologists, and infectious disease specialistsCancer Detection Prevention, 2006
- The growing problem of non-AIDS-defining malignancies in HIVCurrent Opinion in Oncology, 2006
- Serum prostate‐specific antigen levels in older men with or at risk of HIV infectionHIV Medicine, 2006
- Radical prostatectomy in patients infected with human immunodeficiency virusBJU International, 2006
- Detection of humanherpesvirus 8 (HHV-8) in normal prostatesThe Prostate, 2006
- HIV-1 Protease Inhibitor, RitonavirCancer Research, 2004
- INCREASED INCIDENCE OF PATHOLOGICAL AND CLINICAL PROSTATE CANCER WITH AGE: AGE RELATED ALTERATIONS OF LOCAL IMMUNE SURVEILLANCEJournal of Urology, 2004
- Prostate carcinoma among men with human immunodeficiency virus infectionCancer, 2004